Changeflow GovPing Healthcare & Life Sciences Anti-TIGIT Antibodies Treat Cancers, Viral Infe...
Routine Rule Added Final

Anti-TIGIT Antibodies Treat Cancers, Viral Infections

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12606619B2 to Huahui Health Ltd. on April 21, 2026. The patent covers human monoclonal antibodies targeting TIGIT (T-cell immunoreceptor with Ig and ITIM domains) and their use in treating immune-related diseases including cancers and viral infections. Inventors: Jianhua Sui, Fang Yang, Linlin Zhao, Zhizhong Wei. The application includes 21 claims.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12606619B2 to Huahui Health Ltd. on April 21, 2026. The patent covers human monoclonal antibodies against TIGIT (T-cell immunoreceptor with Ig and ITIM domains) and their use in treating immune-related diseases including cancers and viral infections. Inventors: Jianhua Sui, Fang Yang, Linlin Zhao, Zhizhong Wei.\n\nPharmaceutical and biotech companies developing checkpoint inhibitors or immuno-oncology therapies should review this patent for potential freedom-to-operate implications. The patent provides Huahui Health Ltd. with exclusive rights to the anti-TIGIT antibody platform for the specified therapeutic applications.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Human monoclonal antibodies against TIGIT for immune related diseases

Grant US12606619B2 Kind: B2 Apr 21, 2026

Assignee

HUAHUI HEALTH LTD.

Inventors

Jianhua Sui, Fang Yang, Linlin Zhao, Zhizhong Wei

Abstract

The present invention relates to anti-TIGIT antibodies and antigen-binding fragments thereof that bind to both human TIGIT and mouse TIGIT. The present application also provides are nucleotides encoding the antibodies or fragments thereof, compositions or combinations comprising the antibodies or fragments thereof, and uses of the antibodies or fragments thereof in treatment of immune-related disease such as cancers and viral infection.

CPC Classifications

C07K 16/28 C07K 16/2803 C07K 16/2818 C07K 16/2827 C07K 2317/622 C07K 14/70503 C07K 2317/21 C07K 2317/56 C07K 2317/732 C07K 2317/734 C07K 2317/76 C07K 2317/92 A61P 35/00 A61K 2039/505 A61K 2039/507 A61K 2039/545 Y02A 50/30

Filing Date

2021-06-23

Application No.

18145309

Claims

21

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606619B2

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Biologic development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!